1109 Fn QTs
BioCentury & Getty Images

Finance

Nov. 9 Quick Takes: Biogen sheds $14B in value; plus Ambrx’s 200M round, Decibel’s series D and more

Nov 10, 2020 | 5:08 AM GMT

Biogen tumbles after aducanumab panel
After Friday’s FDA advisory committee meeting for Alzheimer’s therapy Aduhelm aducanumab, shares of Biogen Inc. (NASDAQ:BIIB) sank $92.64

Read the full 509 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE